AskBio acquired genomics company Synpromics.

AskBio, the world's foremost clinical stage and gene therapy platform company, acquired Synpromics, the leader in gene control synthetic promoter technology, bioinformatics and intelligent data-driven design. Financial terms were not disclosed. "By combining Synpromics's customized synthetic promoters with AskBio's capsids and Pro10™ manufacturing cell line, we have achieved technical leadership in each of the critical components for successful development of rAAV-based therapeutics," said Sheila Mikhail, CEO and co-founder of AskBio. "With the Synpromics acquisition, we have enhanced our collective ability to develop highly targeted and maximally expressed gene therapies. Today AskBio is better positioned to tackle larger pathway diseases, as we continue our efforts to bring curative therapies for rare disease to patients in need."